CA-CROWN-BIOSCIENCE
Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005031/en/
Mr. Gu joins CrownBio from WuXi Nextcode, a global leader in genomic data analysis, where he was general manager for the China business, as well as chief digital officer. At WuXi Nextcode, John spearheaded a block-chain enabled secure mobile health data bank integrating genomic, clinical and behavioral data for precision healthcare. He also led the effort to apply big data and AI technologies to improve medical genomic interpretation accuracy and efficiency and to improve customer experience via digital technologies.
“I am thrilled to welcome John to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “John brings a wealth of experience in global business and operational transformation, and his deep expertise in the growth of technology platforms will be instrumental in helping CrownBio’s global operations evolve and excel, and at the same time develop our innovative digital and in silico preclinical solutions.”
Prior to WuXi Nextcode, Mr. Gu held successive senior technology and operations roles across digital and technology companies, where he successfully led multiple large-scale global IT transformation projects. This includes Alcatel-Lucent, where John led the IT integration and digital transformation across operations in over 140 countries.
“I am delighted to join CrownBio at this point in time,” said John Gu. “Life science is experiencing exponential growth due to recent developments in science and technologies across multiple disciplines. Through enhanced operational excellence, innovation, and digital technologies, we are well poised to continue to deliver value to our customers.”
Mr. Gu holds an MBA from the University of Chicago, an MS in Computer Science from Loyola University of Chicago, and a double-major BS in Computer Science and Electrical Engineering from Shanghai Jiao Tong University.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.crownbio.com
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200806005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LENOVO25.4.2024 05:01:26 CEST | Press release
Global CIOs geared up to scale AI but organizations aren’t as ready
MUNDIPHARMA24.4.2024 22:02:28 CEST | Press release
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area
MA-BEIGENE24.4.2024 22:02:28 CEST | Press release
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
CA-TSMC24.4.2024 21:31:27 CEST | Press release
TSMC Celebrates 30th North America Technology Symposium with Innovations Powering AI with Silicon Leadership
NV-RIMINI-STREET-INC.24.4.2024 18:51:35 CEST | Press release
Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom